These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7904936)

  • 1. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
    Funck-Brentano C
    Eur Heart J; 1993 Nov; 14 Suppl H():30-5. PubMed ID: 7904936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
    Padrini R; Gusella M; Al Bunni M; Piovan D; Zordan R; Magnolfi G; Maiolino P; Ferrari M
    Br J Clin Pharmacol; 1997 Nov; 44(5):463-70. PubMed ID: 9384463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
    Holubarsch C; Schneider R; Pieske B; Ruf T; Hasenfuss G; Fraedrich G; Posival H; Just H
    Circulation; 1995 Nov; 92(10):2904-10. PubMed ID: 7586258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs.
    Gomoll AW; Bartek MJ
    Eur J Pharmacol; 1986 Dec; 132(2-3):123-35. PubMed ID: 2880732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotropic and haemodynamic effects of d- and d,l-sotalol: comparison with other antiarrhythmics.
    Seipel L; Hoffmeister HM
    Eur Heart J; 1993 Nov; 14 Suppl H():36-40. PubMed ID: 7904937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol.
    Antonaccio MJ; Gomoll A
    Am J Cardiol; 1993 Aug; 72(4):27A-37A. PubMed ID: 8346723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
    Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH;
    Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration/response relations for the multiple antiarrhythmic actions of sotalol.
    Woosley RL; Barbey JT; Wang T; Funck-Brentano C
    Am J Cardiol; 1990 Jan; 65(2):22A-27A; discussion 35A-36A. PubMed ID: 2294688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
    Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
    Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
    Doggrell SA; Brown L
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1625-34. PubMed ID: 11060766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of sotalol.
    Hanyok JJ
    Am J Cardiol; 1993 Aug; 72(4):19A-26A. PubMed ID: 8346722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects.
    Salazar DE; Much DR; Nichola PS; Seibold JR; Shindler D; Slugg PH
    J Clin Pharmacol; 1997 Sep; 37(9):799-809. PubMed ID: 9549633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of class II and class III activity of dl-sotalol in healthy volunteers.
    Kimura M; Umemura K; Ikeda Y; Kosuge K; Nishimoto M; Ohashi K; Nakashima M
    Jpn Heart J; 1998 Jan; 39(1):79-86. PubMed ID: 9601484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class III antiarrhythmics in overdose. Presenting features and management principles.
    Leatham EW; Holt DW; McKenna WJ
    Drug Saf; 1993 Dec; 9(6):450-62. PubMed ID: 8129865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial effect compartment modeling of metoprolol and sotalol: importance of myocardial subsite drug concentration.
    Ritchie RH; Morgan DJ; Horowitz JD
    J Pharm Sci; 1998 Feb; 87(2):177-82. PubMed ID: 9519150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.